

1 Title: Using Trends and Outliers in Managing Delayed Transfusions

2

3 Authors: Burak Bahar^{1,2Δ}, Eric A. Gehrie^{3Δ}, Yunchuan D. Mo^{1,2}, Cyril Jacquot^{1,2} and Meghan

4 Delaney^{1,2}

5 (1) Children's National Hospital, Washington, DC, USA

6 (2) George Washington University, School of Medicine and Health Sciences, Washington, DC,

7 USA

8 (3) American Red Cross, Washington, DC, USA

9 ^ΔCo-first authors

10 Corresponding author:

11 Burak Bahar, MD

12 Children's National Hospital

13 111 Michigan Ave NW

14 Department of Laboratory Medicine

15 Washington, DC, USA

16 202-476-5858

17 bbahar@childrensnational.org

18

19

20

21

22

23

24 Abstract

25 Delayed transfusions may result in patient morbidity and mortality, but no standards for
26 timely transfusion have been developed. Information technology tools could be implemented to
27 identify gaps in provision of blood and to recognize areas of improvement. Herein, we propose
28 that the time to initiate a blood transfusion after an informative laboratory test could feasibly be
29 used by the transfusion medicine service as a metric to monitor for transfusion delays. Trends
30 and outlier events could be further investigated and used to make decisions and implement
31 protocols to improve patient care.

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 Introduction

48 An emerging area of focus within transfusion medicine is the possibility that efforts to
49 curtail unnecessary blood transfusions could unintentionally deprive patients of needed blood
50 transfusions (1). However, the ability to measure or detect transfusions that should have occurred
51 – but did not – is frustrated by the fact that transfusion medicine services generally begin their
52 review at the time of order receipt. In addition, blood shortages could deprive a patient of a
53 needed transfusion even if the clinical indication is recognized by the clinical service (1). The
54 Serious Hazard of Transfusion (SHOT) program defines delayed transfusion as “where a
55 transfusion of a blood component was clinically indicated but was not undertaken or non-
56 availability of blood components led to a significant delay (*e.g.*, that caused patient harm,
57 resulted in admission to ward or return on another occasion for transfusion)” and accepts reports
58 of such events (2). Since 2011, there has been is an increasing trend in the number of annual
59 delayed transfusion reports (3). Per the SHOT 2021 Annual Report, there were 179 delayed
60 transfusion reports and nine deaths in the UK in 2021 (3). SHOT recommended actions to
61 prevent transfusion delays include reviewing, updating and implementing policies, implementing
62 training programs and processes to audit and investigate all transfusion delays, and using
63 appropriate investigation tools (4). We propose that the average (or median) time to initiate a
64 blood transfusion after an informative laboratory test (*e.g.*, haemoglobin concentration or platelet
65 count below local threshold) could be used by the transfusion medicine service as an
66 investigation tool to assess transfusion delays. This metric could also be used to evaluate trends
67 and identify outlier events. This knowledge could help to implement approaches to improve
68 stewardship of the blood supply and minimize the impact of blood shortages.

69

70 Methods

71 From January 1st, 2020, to September 1st, 2022, all patients' complete blood cell (CBC)
72 result and red blood cell (RBC) and platelet transfusion data were extracted, transformed, and
73 loaded into our previously described laboratory data science platform
74 (<https://github.com/bbahar/umay>) (5) with additional custom R and SQL scripts
75 (<https://github.com/bbahar/delayed-transfusions>). The number of RBC and platelet transfusions
76 per week were calculated. Time from the release of laboratory results to the initiation of
77 transfusions were calculated and weekly medians were used for trend analyses. Variables of
78 interest for RBC transfusions were haemoglobin level (<7g/dL and ≥7g/dL), RBC minor
79 antibody presence and Rh status of the recipient, and for platelet transfusion was the platelet
80 count (≤10k/μL, >10 to ≤50k/μL and >50 to ≤150k/μL).

81 Outliers in the time series data were detected utilizing the 'anomalize' R package
82 (version 0.2.2) on R (version 4.0.5). To accommodate for seasonal and trend changes and to find
83 the outliers, data were decomposed using locally estimated scatterplot smoothing (LOESS) and
84 turned into remainder values (*R*) which were compared to their remainder limits (*Rlim*) obtained
85 using generalized extreme studentized deviate (GESD) test. *R* and *Rlim* were calculated using
86 default alpha (width of the normal range), frequency and trend window settings (0.05, 12 to 13
87 weeks and 30 to 45 weeks, respectively). Maximum number of outliers permitted were 2 percent
88 of the data. Results are expressed in mean (standard deviation [SD]) or median (minimum [min],
89 maximum [max]), as appropriate. The study was conducted under Children's National Hospital
90 Institutional Review Board approved study protocol (Pro00010083-Mod00000781 'effectiveness
91 of blood product transfusion and associated adverse events in neonatal & paediatric patients'). A
92 two-tailed Student's *t*-test was performed to assess for significance for continuous variables.

93

94 Results

95 Over the two years and eight months period, 1,587 patients received 10,946 RBC
96 transfusions and 730 patients received 7,704 platelet transfusions within 24 hours of a
97 haemoglobin or a platelet count result, and patients were aged 11.1 years (SD: 7.03) and 10.8
98 years (SD: 7.03), respectively. Average volume of RBC transfusion was 251.7 mL (SD: 95.8),
99 average platelet transfusion volume was 148.9 mL (SD: 79.2), and time to initiate a transfusion
100 was 11.1 hours (SD: 6.82) and 11.1 hours (SD: 7.14), respectively. Mean time to initiate a
101 transfusion was shorter for patients with haemoglobin <7 g/dL (8.67 hours [SD: 5.46]) and
102 platelet count ≤ 10 k/ μ L (7.52 hours [SD: 6.3]) than haemoglobin ≥ 7 g/dL (11.83 hours [SD:
103 6.99]) and platelet count >10 k/ μ L (11.76 hours [SD: 7.09]) (both P : <0.001). On average there
104 were 79 (SD: 25) RBC and 55 (SD: 20) platelet transfusions per week.

105 Dates of outliers for the median time to initiate an RBC or a platelet transfusion after a
106 CBC result were reported in Table 1 and were visualized in Figure 1. Overall, aggregated data
107 assessment demonstrated that there was one outlier week (2020-10-12 to 2020-10-18, R : 7.48
108 [$Rlim$: -6.53 — 6.44]) for all RBC transfusions and none for all platelet transfusions.

109 Investigation of the subgroup data showed that RBC transfusions based on haemoglobin
110 values showed only one outlier week (2020-07-20 to 2020-07-26, R : 6.0 [$Rlim$: -5.46 — 5.62])
111 for a haemoglobin value less than 7 g/dL and none for haemoglobin values ≥ 7 g/dL. Patients
112 with RBC minor antibodies who received RBC transfusion did not have outliers but patients
113 without RBC minor antibodies had two outlier weeks (2021-08-09 to 2021-08-15, R : 7.03; 2022-
114 07-11 to 2022-07-16, R : -7.31 [$Rlim$: 6.47 — 6.13]). A single week was noted to be an outlier

115 (2020-10-12 to 2021-08-15, $R: 7.84$ [$Rlim: -7.38 — 7.07$]) for RBC transfusions for Rh positive
116 patients whereas no outlier weeks were noted for Rh negative patients' RBC transfusions.

117 Assessment of the subgroup platelet transfusions based on pre-transfusion platelet count
118 identified eleven weeks with outliers (2020-05-25 to 2020-05-31, $R: 9.84$; 2020-09-07 to 2020-
119 09-13, $R: 10.7$; 2020-09-14 to 2020-09-20, $R: 9.73$; 2020-10-12 to 2020-10-18, $R: 13.5$; 2021-06-
120 21 to 2021-06-27, $R: 7.11$; 2021-08-30 to 2021-09-05, $R: 13.7$; 2022-01-17 to 2022-01-23, $R:$
121 8.58 ; 2022-01-31 to 2022-02-06, $R:12.4$; 2022-02-07 to 2022-02-13, $R: 6.55$; 2022-05-02 to
122 2022-05-08, $R: 8.63$; 2022-08-08 to 2022-08-14, $R: 5.66$ [$Rlim: -5.93 — 5.41$]) for platelet count
123 ≤ 10 k/ μ L. No outlier weeks were found for platelet transfusions for patients with >10 k/ μ L to
124 ≤ 50 k/ μ L platelet counts, however, two weeks were identified as outliers (2021-10-11 to 2021-
125 10-17, $R: 13.7$; 2022-07-11 to 2022-07-17, $R: 14.6$ [$Rlim: -12.1 — 11.9$]) for platelet transfusions
126 for patients with a platelet count >50 k/ μ L and ≤ 150 k/ μ L.

127

128 Discussion

129 Transfusion medicine service's contingency strategies to mitigate blood shortages
130 depends on the degree of the blood supplier's inventory (*e.g.*, mild: $<25\%$ lower, moderate: 25%
131 to 50% lower, severe: 50% to 75% lower) and duration of the shortage (*e.g.*, short term: <2
132 weeks, long-term: >2 weeks) and includes action items such as lowering transfusion thresholds,
133 restricting orders, preventing wastage, splitting units, recommending pharmacological
134 alternatives, recommending cancelation of non-essential high blood use surgeries, placing upper-
135 limits on blood use for procedures, limiting number of available units at the remote storage
136 refrigerators, lowering the minimum platelet yield required for the hospital to bring a unit into

137 inventory, re-evaluating maintenance RBC exchange for sickle cell disease patients, and as a last
138 resort extending shelf-life of blood products (6-8).

139 Modern machine learning (ML) tools are proposed to help manage operations by
140 translating big data into actionable information (9). Many organizations identified successful use
141 cases for ML tools during the throes of COVID-19 pandemic management (10). Within
142 haematology and transfusion medicine, trend analyses and outlier detections are ML tools which
143 could be utilized to evaluate transfusion delays. Using our proposed metric ‘weekly median time
144 to initiate a transfusion based on an informative laboratory test result’, we have observed trends
145 and identified numerous outliers based on: haemoglobin level, RBC minor antibody presence, Rh
146 status, and platelet count of the patient. Although the number of outlier events were small (one
147 for all RBC transfusions and none for all platelet transfusions), the subgroup analyses for
148 haemoglobin $<7\text{g/dL}$ RBC transfusions and platelet count $\leq 10\text{k}/\mu\text{L}$ platelet transfusions showed
149 three and seven outlier weeks, respectively.

150 Delays causing major morbidity in provision of blood were noted in seven patients in the
151 2021 SHOT report. Five cases were included in the avoidable delays category whereas 14 cases
152 noted in the unavoidable delays category (3). Our transfusion medicine service at Children’s
153 National Hospital was not notified about any severe adverse events due to provision or
154 unavailability of blood for the dates noted as outliers. We propose that the hospital transfusion
155 medicine committees to consider time to initiate a blood transfusion from a laboratory test result
156 which is affecting transfusion decision making (*e.g.*, haemoglobin level or platelet count) as a
157 metric to evaluate trends and outliers in patient’s access to blood products. This information
158 could then be used to conduct investigations for possible missed patient adverse events and be
159 used to address the root cause of the delays or fluctuations in transfusion timing. Furthermore,

160 we propose conducting subgroup assessments (*e.g.*, haemoglobin <7g/dL and platelet count
161 ≤10k/μL transfusions), as we have observed broad analyses might miss significant events for
162 patient subgroups.

163

164

165 References

- 166 1. Rajbhandary S, Andrzejewski C, Fridey J, Stotler B, Tsang HC, Hindawi S, et al. Incorporating the
167 entity of under-transfusion into hemovigilance monitoring: Documenting cases due to lack of inventory.
168 *Transfusion*. 2022;62(3):540-5.
- 169 2. Definitions of current SHOT reporting categories & what to report [July 20, 2022]. Available
170 from: [https://www.shotuk.org/wp-content/uploads/myimages/SHOT-Definitions-active-January-](https://www.shotuk.org/wp-content/uploads/myimages/SHOT-Definitions-active-January-2022.pdf)
171 [2022.pdf](https://www.shotuk.org/wp-content/uploads/myimages/SHOT-Definitions-active-January-2022.pdf).
- 172 3. SHOT Annual Report 2021 [cited July 20, 2022. Available from: [https://www.shotuk.org/wp-](https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2021-FINAL-bookmarked.pdf)
173 [content/uploads/myimages/SHOT-REPORT-2021-FINAL-bookmarked.pdf](https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2021-FINAL-bookmarked.pdf).
- 174 4. Preventing transfusion delays in bleeding and critically anaemic patients [July 20, 2022].
175 Available from:
176 https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=10388
177 [5](https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=10388).
- 178 5. Bahar B, Gehrie EA, Mo YD, Jacquot C, Delanay M. Measuring the Impact of a Blood Supply
179 Shortage Using Data Science. *J Appl Lab Med*. 2022.DOI: 10.1093/jalm/jfac084
- 180 6. Cohn CS, Pagano MB, Allen ES, Frey KP, Gniadek T, Lokhandwala PM, et al. How do I manage
181 long-term blood component shortages in a hospital transfusion service? *Transfusion*. 2020;60(9):1897-
182 904.
- 183 7. McGinnis E, Guo RJ, Marcon KM, Berry B, Coupland R, Meneghetti V, et al. Adaptations of
184 transfusion systems to the COVID-19 pandemic in British Columbia, Canada: Early experiences of a large
185 tertiary care center and survey of provincial activities. *Transfusion*. 2021;61(4):1102-11.
- 186 8. Saillant NN, Kornblith LZ, Moore H, Barrett C, Schreiber MA, Cotton BA, et al. The National Blood
187 Shortage-An Impetus for Change. *Ann Surg*. 2022;275(4):641-3.
- 188 9. McAfee A, Brynjolfsson E. Big data: the management revolution. *Harv Bus Rev*. 2012;90(10):60-
189 6, 8, 128.
- 190 10. Piccarozzi M, Aquilani B. The role of Big Data in the business challenge of Covid-19: a systematic
191 literature review in managerial studies. *Procedia Comput Sci*. 2022;200:1746-55.

192

193

194

195

196 Table 1. Dates of outliers for weekly median time to initiate a red blood cell or a platelet
 197 transfusion following a haemoglobin, or a platelet count result and based on the haemoglobin
 198 level, red blood cell minor antibody presence, Rh status, and platelet count of the patient.

Variable		Dates of outliers	R	Rlim
All RBC transfusions		2020-10-12 to 2020-10-18	7.48	-6.53 — 6.44
RBC transfusions based on haemoglobin level				
	< 7g/dL	2020-07-20 to 2020-07-26	6.0	-5.46 — 5.61
	≥ 7g/dL	None		
RBC transfusions and antibody presence				
	Antibody positive	None		
	Antibody negative	2021-08-09 to 2021-08-15	7.03	-6.47 — 6.13
		2022-07-11 to 2022-07-17	-7.31	-6.47 — 6.13
RBC transfusion and Rh status of recipient				
	Rh positive	2020-10-12 to 2021-08-15	7.84	-7.38 — 7.07
	Rh negative	None		
All platelet transfusions		None		
Platelet transfusions based on platelet count				
	≤10k/μL	2020-05-25 to 2020-05-31	9.84	-5.93 — 5.41
		2020-09-07 to 2020-09-13	10.7	-5.93 — 5.41
		2020-09-14 to 2020-09-20	9.73	-5.93 — 5.41

		2020-10-12 to 2020-10-18	13.5	-5.93 — 5.41
		2021-06-21 to 2021-06-27	7.11	-5.93 — 5.41
		2021-08-30 to 2021-09-05	13.7	-5.93 — 5.41
		2022-01-17 to 2022-01-23	8.58	-5.93 — 5.41
		2022-01-31 to 2022-02-06	12.4	-5.93 — 5.41
		2022-02-07 to 2022-02-13	6.55	-5.93 — 5.41
		2022-05-02 to 2022-05-08	8.63	-5.93 — 5.41
		2022-08-08 to 2022-08-14	5.66	-5.93 — 5.41
	>10 to ≤50k/μL	None		
	>50 to ≤150k/μL	2021-10-11 to 2021-10-17	13.7	-12.1 — 11.9
		2022-07-11 to 2022-07-17	14.6	-12.1 — 11.9

199 RBC: red blood cell; *R*: remainder value; *Rlim*: remainder limits

200

201

202

203

204

205

206

207

208

209 Figure 1. Visual representation of outlier weeks of median time to initiate a red blood cell or a

210 platelet transfusion following a haemoglobin, or a platelet count result and based on the

211 haemoglobin level, red blood cell minor antibody presence, Rh status, and platelet count of the
212 patient.

